Literature DB >> 28735762

Parathyroidectomy for tertiary hyperparathyroidism: A systematic review.

Jessica A Tang1, Jacob Friedman1, Michelle S Hwang1, Anna M Salapatas1, Lauren B Bonzelaar1, Michael Friedman2.   

Abstract

OBJECTIVE: Analyze the efficacy and indications for parathyroidectomy as an intervention for tertiary hyperparathyroidism. DATA SOURCES: PubMed, MEDLINE, and Cochrane Library databases. REVIEW
METHODS: A systematic literature search was performed using the. Original research articles in English were retrieved using the search terms ("tertiary hyperparathyroidism" OR "3HPT") AND "parathyroidectomy". Articles were analyzed in regards to their surgical indications, operative endpoints, comparison between different surgical interventions, characterization of disease recurrence rates, and evaluation of alternative medical management.
RESULTS: Thirty studies met the criteria for inclusion. Among the studies that report indications for parathyroidectomy, persistent hypercalcemia as well as clinical manifestations of hypercalcemia despite medical therapy predicted which patients would eventually need surgical intervention. The majority of studies comparing the extent of parathyroidectomy recommended a more focused approach to parathyroidectomy when warranted. All studies found that parathyroidectomy was an effective treatment for 3HPT. Three studies discussed alternative conservative approaches.
CONCLUSION: Interestingly, hyperparathyroidism alone is not an indication for surgery without other findings; rather, symptomatic hypercalcemia appears to be the main indication. Most studies recommend limited or subtotal parathyroidectomy for 3HPT. The operative endpoint of surgery is not necessarily a return of PTH to normal, but a >50% drop in PTH level even if PTH remains above normal. Additionally, "success" or "cure" is defined as normal calcium levels regardless of whether or not PTH is elevated. It appears the goal of surgery for 3HPT is not a normal PTH value, but a normal calcium level at least six months postoperatively.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28735762     DOI: 10.1016/j.amjoto.2017.06.009

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  7 in total

Review 1.  Pediatric hyperparathyroidism: review and imaging update.

Authors:  Hedieh Khalatbari; Safia H E Cheeney; Scott C Manning; Marguerite T Parisi
Journal:  Pediatr Radiol       Date:  2021-04-27

2.  Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia.

Authors:  Manabu Okada; Yoshihiro Tominaga; Tetsuhiko Sato; Toshihide Tomosugi; Kenta Futamura; Takahisa Hiramitsu; Toshihiro Ichimori; Norihiko Goto; Shunji Narumi; Takaaki Kobayashi; Kazuharu Uchida; Yoshihiko Watarai
Journal:  BMC Nephrol       Date:  2022-06-17       Impact factor: 2.585

3.  Refractory hypercalcemia due to an ectopic mediastinal parathyroid gland in a hemodialysis patient: a case report.

Authors:  Yingjing Shen; Peipei Fei
Journal:  BMC Nephrol       Date:  2019-05-14       Impact factor: 2.388

4.  The role of 18F-FCH PET/CT in patients with uremic hyperparathyroidism compared with 99mTc-sestaMIBI SPECT/CT and ultrasonography.

Authors:  Yu Xue; Wenbo Li; Zhu Xia; Chengming Lei; Yiyi Cao; Zhengjie Wang; Hua Pang
Journal:  EJNMMI Res       Date:  2019-12-26       Impact factor: 3.138

5.  Parathyroid Carcinoma in the Setting of Tertiary Hyperparathyroidism: Case Report and Review of the Literature.

Authors:  Federico Cappellacci; Fabio Medas; Gian Luigi Canu; Maria Letizia Lai; Giovanni Conzo; Enrico Erdas; Pietro Giorgio Calò
Journal:  Case Rep Endocrinol       Date:  2020-12-02

6.  Parathyroidectomy in chronic kidney disease.

Authors:  Lillian Andrade da Rocha; Murilo Catafesta das Neves; Fabio Luiz de Menezes Montenegro
Journal:  J Bras Nefrol       Date:  2021-12-03

7.  Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a.

Authors:  Masatsune Itoh; Michiko Okajima; Yuko Kittaka; Akihiro Yachie; Taizo Wada; Yutaka Saikawa
Journal:  Bone Rep       Date:  2022-04-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.